KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Retained Earnings: 2009-2024

Historic Retained Earnings for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to -$2.2 billion.

  • Ionis Pharmaceuticals' Retained Earnings fell 11.95% to -$2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 billion, marking a year-over-year decrease of 11.95%. This contributed to the annual value of -$2.2 billion for FY2024, which is 25.27% down from last year.
  • According to the latest figures from FY2024, Ionis Pharmaceuticals' Retained Earnings is -$2.2 billion, which was down 25.27% from -$1.8 billion recorded in FY2023.
  • In the past 5 years, Ionis Pharmaceuticals' Retained Earnings ranged from a high of -$1.1 billion in FY2020 and a low of -$2.2 billion during FY2024.
  • Over the past 3 years, Ionis Pharmaceuticals' median Retained Earnings value was -$1.8 billion (recorded in 2023), while the average stood at -$1.8 billion.
  • Data for Ionis Pharmaceuticals' Retained Earnings shows a maximum YoY tumbled of 59.89% (in 2020) over the last 5 years.
  • Ionis Pharmaceuticals' Retained Earnings (Yearly) stood at -$1.1 billion in 2020, then dropped by 2.53% to -$1.2 billion in 2021, then dropped by 23.25% to -$1.4 billion in 2022, then decreased by 25.62% to -$1.8 billion in 2023, then dropped by 25.27% to -$2.2 billion in 2024.